Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

Launch and Funding:
Ouro Medicines, a biotechnology company, has launched with $120 million in funding to develop immune reset therapeutics for chronic immune-mediated diseases12.

Founding and Partnerships:
Ouro was founded by Monograph Capital in partnership with GSK plc. The Series A funding was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with participation from other investors14.

Focus:
The company focuses on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression14.

Lead Program:
Ouro’s most advanced product candidate is OM336, a BCMA-directed, bispecific T cell engager recently licensed from Keymed Biosciences4.

Discovery Programs:
Ouro intends to advance a broad set of discovery programs targeting additional dimensions of B cell biology, aiming to drive innovative treatments for chronic immune-mediated diseases14.

Leadership:
The company has assembled a leadership team with expertise in relevant diseases and modalities, including Jaideep Dudani, PhD, as Chief Executive Officer1.

Investor Support:
TPG Life Sciences Innovations, NEA, and Norwest Venture Partners have expressed strong support for Ouro’s mission to develop immune reset therapeutics that address serious unmet needs for patients14.

Sources:

1. https://www.prnewswire.com/news-releases/ouro-medicines-launches-to-define-the-future-of-treatment-for-people-with-immune-mediated-diseases-302347583.html

2. https://www.vcnewsdaily.com/access/getarticle.php?aid=jstpnhkngx

4. https://www.goodwinlaw.com/en/news-and-events/news/2025/01/announcements-lifesciences-vc-goodwin-advises-ouro-medicines-on-its-120-million